Soluble interleukin-2 receptor in Crohn's disease: relation of serum concentrations to disease activity.

Crabtree, J. E.; Juby, L. D.; Heatley, R. V.; Lobo, Alan; Bullimore, D W; Axon, A. T. R.

doi:10.1136/gut.31.9.1033

Cited by 66 publications

(17 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, IL-IO serum levels seem lo reflect disease activity in UC and CD. Similar correlation has also been described for serum levels of IL-6 and sIL-2 [26,27]. We examined daily variations of IL-IO levels in highly active UC and CD patients under treatment with intravenous steroids.…”

Section: Discussionsupporting

confidence: 60%

Circulating antiinflammatory cytokine IL-10 in patients with inflammatory bowel disease (IBD)

Kucharzik

Stoll

Lügering

et al. 1995

Clinical and Experimental Immunology

139

View full text Add to dashboard Cite

SUMMARY IBD is characterized by increased serum concentrations of different cytokines. IL‐10 inhibits the production of proinflammatory cytokines such as IL‐1, tumour necrosis factor‐alpha (TNF‐a), interferon‐gamma (IFN‐γ) and IL‐6 through inhibitory action on Th1 cells and macrophages, and it is thought to be a suppressor type cytokine. In the present study we determined serum concentrations of IL‐10 in patients with ulcerative colitis (UC) and Crohn's disease (CD). We measured human IL‐10 by our own newly established ELISA system using PharMingen antibodies. Serum antibodies were assessed in 44 patients with UC, 40 patients with CD, and in 30 healthy controls. Human IL‐10 serum levels were significantly increased in patients with active UC (144 ± 34 pg/ml (mean ± s.e.m.), P <0.001) and in active CD (132 ± 32 pg/ml, P <0.001) compared with healthy controls (44.9.5pg/ml). Only patients with active CD and active UC presented with significantly increased IL‐10 serum levels, while patients with inactive disease did not show any significant increase. There was no statistically significant difference between IL‐10 serum levels in patients with CD or UC. Compared with clinical disease activity indices there was a significant correlation between IL‐10 serum concentration and CDAI in patients with CD (r= 0.45, P <0.01) and CAI in VC patients (r= 0.39, P <0.05). Comparing IL‐10 serum levels with serum concentrations of other proinflammatory cytokines there was a significant correlation to scrum levels of sIL‐2R (r= 0.417, P <0.05) and IL‐6 (r= 0.387, P <0.05) in patients with CD. Serum cytokine levels in patients with UC did not show any significant correlation to IL‐10 serum concentration. IL‐10 is elevated in serum of patients with active CD and UC. suggesting that IL‐10 acts as a naturally occurring damper in the acute inflammatory process of IBD.

show abstract

Section: Discussionsupporting

confidence: 60%

Circulating antiinflammatory cytokine IL-10 in patients with inflammatory bowel disease (IBD)

Kucharzik

Stoll

Lügering

et al. 1995

Clinical and Experimental Immunology

139

View full text Add to dashboard Cite

show abstract

“…Elevated serum levels of IL-2 and sIL-2R have been found in diseases associated with increased immune activation, such as rheu matoid arthritis [11], parasitic infections [12] and in some virus infections [13]. In this study elevated serum concentrations of sIL-2R mirrored the intestinal inflammation in up to 90% of the patients with active CD and UC, thus confirming results recently reported by other authors [14][15][16][17][18]. In CD, a correlation between elevated sIL-2 levels and the disease activity as assessed by the Harvey-Bradshaw index has been shown before [15.…”

Section: Discussionsupporting

confidence: 91%

Soluble lnterleukin-2 Receptor, lnterleukin-6 and Interleukin-1 β in Patients with Crohn’s Disease and Ulcerative Colitis: Preoperative Levels and Postoperative Changes of Serum Concentrations

Schürmann¹,

Betzler²,

Post³

et al. 1992

Digestion

View full text Add to dashboard Cite

Crohn’s disease (CD) and ulcerative colitis (UC) show an intestinal activation of T cells and macrophages within the inflamed lesions. The aim of the present prospective study was to determine whether circulating interleukins (IL) represent useful markers of immune activation in vivo and to characterize their respective roles in monitoring disease activity. Serum concentrations of the soluble IL-2 receptor (sIL-2R), IL-6 and IL-1 β were measured in 10 patients with CD and 10 patients with UC before, at day 10 and 2 years after resection of inflamed bowel segments. The data were correlated with neopterin, C-reactive protein and other standard parameters of disease activity. Preoperatively, mean sIL-2R concentration was 495 ± 62 U/ml (mean ± SEM; healthy controls: 210 ± 25 U/ml; p < 0.02) in CD and 705 ± 120 U/ml (p < 0.00002) in UC. The corresponding IL-6 serum concentrations were 37 + 6 U/ml in CD (controls: 11 ± 0.6 U/ml; p < 0.0036) and 33 ± 6 U/ml (p < 0.04) in UC. Two years postoperatively, sIL-2R was still elevated in 6 out of 9 patients in both disease groups. These patients did not differ from the remaining group with respect to disease activity. Serum IL-6, elevated in 7 patients with CD and in 6 patients with UC at day 10 postoperatively, had returned to normal in all patients by this time. There was a significant correlation between sIL-2R and neopterin (r = 0.52; p < 0.02) and between IL-6 and C-reactive protein (r = 0.44; p < 0.05) but not between sIL-2R and C-reactive protein. The sensitivity of increased concentrations of sIL-2R and IL-6 to reflect active CD and UC is comparable to that of neopterin and C-reactive protein.

show abstract

“…Increased concentrations of sIL-2R in plasma or serum and urine have been demonstrated in clinical conditions characterized by T-cell activation in vivo, such as renal (44, (56), and certain chronic immunoinflammatory disorders (47,57,58). Significantly increased serum concentrations of s I L -~R , which correlate with plasma orosomucoid concentrations and disease activity, have consistently been demonstrated in IBD patients (48,(59)(60)(61). Recently, increased sIL-2R levels have also been detected in endoscopic mucosal biopsy specimens from patients with active IBD (12,60).…”

Section: Reviewmentioning

confidence: 99%

Cytokines in Inflammatory Bowel Disease

Brynskov

Nielsen²,

Ahnfelt-Rønne³

et al. 1992

Scandinavian Journal of Gastroenterology

View full text Add to dashboard Cite

Soluble interleukin-2 receptor in Crohn's disease: relation of serum concentrations to disease activity.

Cited by 66 publications

References 23 publications

Circulating antiinflammatory cytokine IL-10 in patients with inflammatory bowel disease (IBD)

Circulating antiinflammatory cytokine IL-10 in patients with inflammatory bowel disease (IBD)

Soluble lnterleukin-2 Receptor, lnterleukin-6 and Interleukin-1 β in Patients with Crohn’s Disease and Ulcerative Colitis: Preoperative Levels and Postoperative Changes of Serum Concentrations

Cytokines in Inflammatory Bowel Disease

Contact Info

Product

Resources

About